Microangiopathy in Cancer: Causes, Consequences, and Management.
Cancer Treat Res
; 179: 151-158, 2019.
Article
em En
| MEDLINE
| ID: mdl-31317486
ABSTRACT
Thrombotic microangiopathy (TMA) is a syndrome involving fragmentation haemolysis, thrombocytopenia, and thrombosis. A range of disorders including cancer may have TMA as a clinical manifestation. TMA in cancer may be caused by several mechanisms, including systemic microvascular metastases, but may also be due to extensive bone marrow involvement with cancer or secondary necrosis. Chemotherapeutic agents may also cause associated TMA through a range of different mechanisms. Gemcitabine, platinum-based drugs, mitomycin C, and proteasome inhibitors are known to cause TMA in cancer patients. Transplant-associated TMA (TA-TMA) may affect either solid organ or HSCT patients. TA-TMA remains a difficult complication to address due to its high mortality rate, lack of standard diagnostic criteria, and limited therapeutic options. The challenge of cancer-associated TMA is furthered by the fact that plasma exchange is ineffective in its management.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Microangiopatias Trombóticas
/
Neoplasias
/
Antineoplásicos
Tipo de estudo:
Etiology_studies
Limite:
Humans
Idioma:
En
Revista:
Cancer Treat Res
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
Reino Unido